Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) earnings
KNSA earnings moved a median of -0.26% by the close. Quarterly and annual KNSA reports and results, each read against the price at its own news timestamp. Back to the KNSA overview →
30 measured KNSA earnings events.
Where these KNSA earnings landedvs 29 measured KNSA earnings reactions
| Middle 50% of KNSA earnings reactions | -1.70% to +3.39% |
|---|---|
| Median reaction (to close) | -0.26% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 KNSA earnings events with a measured close landed between -1.70% and +3.39%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Kiniksa Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -2.20% | -0.63% | |
| Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | Press release | +6.21% | +12.94% | |
| Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026 | Press release | -0.16% | -0.81% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -0.76% | -1.71% | |
| Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | Press release | +5.27% | +15.06% | |
| Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026 | Press release | -0.88% | -0.49% | |
| Form 10-K Kiniksa Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -0.94% | -1.70% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -2.14% | -4.86% | |
| Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | Press release | -9.88% | -4.48% | |
| Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025 | Press release | +0.58% | -0.26% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -0.07% | -2.50% | |
| Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | Press release | +2.21% | — | |
| Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025 | Press release | -0.07% | -2.37% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -0.08% | +3.65% | |
| Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution | Press release | +10.93% | +16.42% | |
| Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025 | Press release | +1.32% | +4.83% | |
| Form 10-K Kiniksa Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -0.07% | -1.40% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -0.73% | -1.25% | |
| Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution | Press release | +9.99% | +9.12% | |
| Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 | Press release | +2.62% | +0.34% | |
| Form 10-Q Kiniksa Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +0.08% | +0.58% | |
| Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution | Press release | +0.93% | +13.07% | |
| Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024 | Press release | +0.04% | -2.77% | |
| Form 10-Q Kiniksa Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | +0.45% | +1.13% | |
| Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution | Press release | +0.76% | +3.39% | |
| Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024 | Press release | +0.17% | -3.36% | |
| Form 10-K Kiniksa Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | -0.26% | +1.54% | |
| Form 10-Q Kiniksa Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | +1.35% | -0.61% | |
| Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution | Press release | -0.94% | +2.35% | |
| Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023 | Press release | +0.00% | +0.13% |
Keep exploring
More KNSA: analyst actions → · SEC filings → · KNSA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| LeMaitre Vascular, Inc. (LMAT) | 430 | +0.05% | 54% |
| TRULIEVE CANNABIS CORP (TCNNF) | 429 | +0.41% | 58% |
| Veracyte, Inc. (VCYT) | 427 | -0.15% | 46% |
| Moleculin Biotech, Inc. (MBRX) | 426 | -0.21% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.